JUDAH JUDAH FOLKMAN

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Is angiogenesis an organizing principle in biology and medicine?
    Judah Folkman
    Children s Hospital Boston, Department of Surgery and Vascular Biology Program, Harvard Medical School, Karp Family Research Laboratories 12 129, Boston, MA 02115 5737, USA
    J Pediatr Surg 42:1-11. 2007
  2. ncbi request reprint Endogenous angiogenesis inhibitors
    Judah Folkman
    Departments of Surgery, Children s Hospital and Harvard Medical School and Vascular Biology Program, Children s Hospital, Boston, Massachusetts 02115, USA
    APMIS 112:496-507. 2004
  3. ncbi request reprint Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action
    Judah Folkman
    Children s Hospital Harvard Medical School, Cambridge, MA, USA
    Exp Cell Res 312:594-607. 2006
  4. ncbi request reprint Angiogenesis
    Judah Folkman
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115 5737, USA
    Annu Rev Med 57:1-18. 2006
  5. ncbi request reprint Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Sci STKE 2006:pe35. 2006
  6. ncbi request reprint Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007

Research Grants

Detail Information

Publications6

  1. ncbi request reprint Is angiogenesis an organizing principle in biology and medicine?
    Judah Folkman
    Children s Hospital Boston, Department of Surgery and Vascular Biology Program, Harvard Medical School, Karp Family Research Laboratories 12 129, Boston, MA 02115 5737, USA
    J Pediatr Surg 42:1-11. 2007
  2. ncbi request reprint Endogenous angiogenesis inhibitors
    Judah Folkman
    Departments of Surgery, Children s Hospital and Harvard Medical School and Vascular Biology Program, Children s Hospital, Boston, Massachusetts 02115, USA
    APMIS 112:496-507. 2004
    ....
  3. ncbi request reprint Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action
    Judah Folkman
    Children s Hospital Harvard Medical School, Cambridge, MA, USA
    Exp Cell Res 312:594-607. 2006
    ....
  4. ncbi request reprint Angiogenesis
    Judah Folkman
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115 5737, USA
    Annu Rev Med 57:1-18. 2006
    ..Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curve of efficacy. "Antiangiogenic chemotherapy" is a novel approach to the treatment of drug resistance...
  5. ncbi request reprint Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Sci STKE 2006:pe35. 2006
    ..Thus, p53 guards the genome from cancer by controlling the three fundamental processes that are critical for growth of a primary tumor and its metastases-tumor cell proliferation, apoptosis, and tumor angiogenesis...
  6. ncbi request reprint Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ....

Research Grants25

  1. CIRCULATING INHIBITORS OF ENDOTHELIAL CELL GROWTH
    Judah Folkman; Fiscal Year: 2003
    ..A study of mechanism of endogenous inhibitors may enlarge their understanding of the family of proteins which operate to suppress angiogenesis under physiological conditions. ..
  2. MECHANISMS OF ANGIOGENESIS IN TRANSGENIC TUMORIGENESIS
    Judah Folkman; Fiscal Year: 2004
    ..4. Further develop experimental therapeutic approaches that utilize angiogenesis inhibitors for treatment or prevention of endogenous cancers in transgenic mouse models. ..
  3. CIRCULATING INHIBITORS OF ENDOTHELIAL CELL GROWTH
    Judah Folkman; Fiscal Year: 1999
    ....
  4. CIRCULATING INHIBITORS OF ENDOTHELIAL CELL GROWTH
    Judah Folkman; Fiscal Year: 2007
    ..Currently, all angiogenesis inhibitors in clinical application are employed only after the angiogenic switch. ..